[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Il-Yang Pharm. Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":133},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,64,85,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100626278","phase-1-safety-tolerability-pharmacokinetic-and-pharmacodynamic-of-iy-828026-in-healthy-volunteers-100626278",false,"NCT07433556","Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers","A Randomized, Double-blinded, Partial-open, Placebo\u002FActive-controlled, Single\u002FMultiple Dosing, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Characteristics of IY-828026 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult volunteers aged ≥ 19 and ≤ 50 years at screening\n* Body weight ≥ 50.0 kg to ≤ 90.0 kg and body mass index (BMI) of ≥ 18.5 kg\u002Fm2 to ≤ 29.9 kg\u002Fm2 at screening\n* Volunteers who were fully informed of and completely understood this study, voluntarily agreed to participate, and provided written consent to comply with the precautions\n\nExclusion Criteria:\n\n* Current or history of clinically significant disease of hepatobiliary (severe hepatic impairment, viral hepatitis, etc.), renal (severe renal impairment, etc.), nervous, immune, respiratory, gastrointestinal, endocrine, hemato-oncologic, cardiovascular (heart failure, torsades de pointes, etc.), urinary, or psychiatric (mood disorder, obsessive compulsory disorder, etc.) system or sexual dysfunctions\n* H. pylori eradication treatment within 6 months or positive result for H. pylori at screening\n* Hypersensitivity or history of clinically significant hypersensitivity to PPIs, P-CABs, and other drugs (aspirin, antibiotics, etc.)\n* A positive result in serology (hepatitis B tests, hepatitis C tests, human immunodeficiency virus \\[HIV\\] tests, or syphilis tests)\n* History of drug abuse or positive results for drug abuse in the urine drug screen",true,"ALL","19 Years","50 Years",{"count":21,"type":22},86,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","A randomized, double-blinded, partial-open, placebo\u002Factive-controlled, single\u002Fmultiple dosing, dose escalation phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of IY-828026 in healthy adult volunteers",[28],"Healhty","RECRUITING","2026-03-23",{"date":32,"type":33},"2026-03-27","ACTUAL",{"date":30,"type":33},{"date":36,"type":22},"2027-06",{"name":38,"class":39},"Il-Yang Pharm. Co., Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100537980","phase-3-study-to-evaluate-the-efficacy-and-safety-of-ilaprazole-10-mg-in-prevention-nsaids-associated-peptic-ulcer-100537980","NCT06284876","Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer","A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer","Inclusion Criteria:\n\n1. Adult males and females aged 19 years or older on the day of informed consent\n2. Subjects requiring continuous treatment or receiving treatment with NSAIDs\n3. Subjects with at least one of following peptic ulcer risk factors at the time of Screening\n4. Subjects who have provided voluntary informed consent for the study participation after the study is explained\n\nExclusion Criteria:\n\n1. Subjects with Gastroesophageal varices, Esophageal stricture or ulcerous stenosis, Gastrointestinal bleeding or perforation, Esophageal dysplasia and else based on the screening EGD results.\n2. Subjects with inflammatory bowel diseases, pancreatitis, pyloric obstruction, and primary esophageal motility disorder\n3. Subjects with confirmed history of malignancy within 5 years prior to Screening\n4. Positive human immunodeficiency virus (HIV) antigen\u002Fantibody at Screening",{"count":49,"type":22},416,[51],"PHASE3","To demonstrate the non-inferiority of Ilaprazole 10 mg to the active control in prevention of NSAIDs-associated peptic ulcer, as assessed by the proportion of subjects with peptic ulcer by Week 24",[54],"Peptic Ulcer","2025-05-25",{"date":57,"type":33},"2025-05-30",{"date":59,"type":33},"2024-07-23",{"date":61,"type":22},"2027-02-28",{"name":38,"class":39},2,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":63},"100567224","efficacy-and-safety-of-dose-redution-of-radotinib-as-a-first-line-treament-in-ph-cml-100567224","NCT06665412","Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML","A Single-arm, Open-label, Multicenter, Investigator-led Observational Study to Evaluate the Efficacy and Safety of Dose Reduction of Radotinib as a First-line Treatment in Patients With Newly Diagnosed Chronic Phase Ph+ Chronic Myeloid Leukemia.","Inclusion Criteria:\n\n1. Male or female patients aged 19 years old or older\n2. Patients with confirmed diagnosis of chronic phase CML within last 8weeks(throung chromosome testing or bone marrow testing)\n\n   * Chronic phase CML is defined as follows:\n\n     * Blast in peripheral blood and bone marrow \\\u003C15%\n\n       * The sum of blast and promyelocyte in peripheral blood and bone marrow \\\u003C30%\n\n         * Basophil in peripheral blood \\\u003C20%\n\n           * Platelets count ≥ 50 × 109\u002FL (≥ 50,000\u002Fmm3) (But, transient prior therapy related thrombocytopenia \\[\\\u003C50 × 109\u002FL (\\\u003C 50,000\u002Fmm3)\\] is acceptable)\n\n             * No extramedullary involvement other than enlargements of liver and spleen\n3. Patients with positive Philadelphia chromosome and confirmed expression of BCR:ABL1 transcript\n4. ECOG scale 0, 1 or 2\n5. Patients who have adequate organ functions as defined below:\n\n   * Total bilirubin \\\u003C 1.5 × upper limit of normal (ULN)\n   * SGOT and SGPT \\\u003C 2.5× ULN\n   * Creatinine \\\u003C 1.5 × ULN\n   * Serum amylase and lipase ≤ 1.5 × ULN\n   * Alkaline Phosphatase ≤ 2.5 × ULN (only if not related to the tumor)\n6. Women of childbearing potential should have a negative serum or urine pregnancy test\n7. Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month (4 weeks) after the last dose of investigational product in such a manner that the risk of pregnancy is minimized.\n8. Patients providing written informed consent form before the study related screening procedures.\n\nExclusion Criteria:\n\n1. Patients with Philadelphia chromosome negative\n2. Patients who used Radotinib for 8 days or longer before study entry\n3. Patients who had been treated with other targeted anti-cancer therapy, except for Hydrea or Agrylin, which inhibits the growth of leukemic cells\n4. Patients who have hypersensitivity to active ingredient or any of the excipients of this investigational product.\n5. Patients with impaired cardiac function as defined below:\n\n   * Patients who cannot have QT intervals measured according to ECG\n\n     * Complete left bundle branch block\n\n       * Patients with cardiac pacemakers\n\n         * Patients with congenital long QT syndrome or the family history of known long QT syndrome\n\n           * The mean QTcF \\>450msec ECG tests at baseline\n\n             * Clinically significant resting bradycardia (\\\u003C 50 bpm) History of, or presence of symptomatic ventricular or atrial tachyarrhythmias\n\n               * Clinically significant resting bradycardia (\\\u003C 50 bpm)\n\n                 * Medical history of clinically confirmed myocardial or infarctionof unstable angina (within last 12 months)\n\n                   * Other clinically significant cardiac disease (e.g. congestive heart failure, or uncontrolled hypertension)\n6. Cytologically confirmed CNS involvement (if asymptomatic, spinal fluid examination is not necessary prior to first treatment)\n7. Severe or uncontrolled chronic medical condition (e.g., uncontrolled diabetes, active or uncontrolled infection)\n8. Other significant congenital or acquired bleeding disorders that are not related to underlying leukemia\n9. Patients who previously received radiotherapy to at least 25% of the bone marrow\n10. Patients who had a major surgery within 4 weeks prior to study entry or has not recovered from side effects of such surgery\n11. Patients who diagosed with another clinically significant malignant tumor wihin 5years before study etnry, excluding basal cell carcinoma\n12. Patients who are currently receiving treatment with a strong CYP3A4 inhibitor (e.g., erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil) or CYP3A4 inducer (e.g., dexamthasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbitol, St. John's Wort). Treatment cannot be safely discontinued or switched to a different medication prior to initiation of study treatment\n13. Patients who are currently receiving treatment with a medication that has the potential to prolong the QT interval. Treatment cannot be safely discontinued or switched to a different medication prior to initiation of study treatment\n14. Impairment of GI function or GI disease that may significantly alter absorption of study drugs (e.g., ulcerative colitis, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, GI bypass surgery).\n15. History of acute or chronic pancreatitis within last one year\n16. Acute or chronic liver or pancreas disease or severe renal disease\n17. Patients with HbsAg, HCV Ab positive\n\n    * following subjects can be enrolled.\n\n      * Inactive hepatitis B surface antigen (HBsAg) carriers(site specific local lab normal range lower limit assessed by investigator)\n      * undergoding HCV Ab or HCV RNA testing judged by investigator to be eligible for enroll\n18. History of HIV Ab positive or confirmed HIV Ab positvie.\n19. Pregnant or the women with breast-feeding 2",{"count":72,"type":22},168,"OBSERVATIONAL","The goal of this observational study is to learn about the efficacy and safety profile when Radotinib dose redution is performed in Ph+ CML subjects.\n\nThe main efficacy is checked by MMR rate by 12 months from IP treatment.",[76],"Chronic Phase Ph+ Chronic Myeloid Leukemia","2024-10-28",{"date":79,"type":33},"2024-10-30",{"date":81,"type":33},"2024-10-24",{"date":83,"type":22},"2026-12-31",{"name":38,"class":39},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100321030","phase-3-a-phase-3-study-for-the-efficacy-and-safety-of-radotinib-in-cp-cml-patients-with-failure-or-intolerance-to-previous-tkis-100321030","NCT03459534","A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs","A Phase 3 Multinational, Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Ph+ Chronic Phase Chronic Myeloid Leukemia Patients With Failure or Intolerance to Previous TKIs Therapy Including Imatinib","Inclusion Criteria:\n\n1. Male or female patients aged 18 years old\n2. Chronic Phase Ph+ Chronic Myeloid Leukemia patients who failed or intolerance the previous TKIs therapy including Imatinib Imatinib\n3. ECOG scale 0, 1 or 2\n4. Chronic phase is defined as all of the following conditions that subjects meet.\n\n   * Blast in peripheral blood and bone marrow \\\u003C15%\n   * The sum of blast and promyelocyte in peripheral blood and bone marrow \\\u003C30%\n   * Basophil in peripheral blood \\\u003C20%\n   * Platelets count ≥50 × 10\\^9\u002FL (≥ 50,000\u002Fmm3) (But, transient prior therapy related thrombocytopenia \\[\\\u003C 50 × 109\u002FL (\\\u003C 50,000\u002Fmm3)\\] is acceptable\n   * No evidence of involvement of extramedullary leukemia other than enlargements of liver and spleen\n5. Patients who have adequate organ functions as defined below:\n\n   * Total bilirubin \\\u003C 1.5 × upper limit of normal (ULN)\n   * SGOT and SGPT \\\u003C 2.5× ULN\n   * Creatinine \\\u003C 1.5 × ULN\n   * Serum amylase and lipase ≤ 1.5 × ULN\n   * Alkaline Phosphatase ≤ 2.5 × ULN (only if not related to the tumor)\n6. Women of childbearing potential should have a negative serum or urine pregnancy test within 14 days of the enrollment.\n7. Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month (4 weeks) after the last dose of investigational product in such a manner that the risk of pregnancy is minimized.\n\nExclusion Criteria:\n\n1. Patients who have been diagonised accelerated phase and blast crisis CML in previous therapy if only once.\n2. Patients with CCyR at the time of screening\n3. Any below impaired cardiac function:\n\n   * LVEF \\\u003C45% or \\\u003C lower bound of normal limit of study site (whichever higher), confirmed by echocardiogram at the site\n   * Patients who cannot have QT intervals measured according to ECG\n   * Complete left bundle branch block\n   * Patients with cardiac pacemakers\n   * Patients with congenital long QT syndrome or the family history of known long QT syndrome\n   * History of, or presence of symptomatic ventricular or atrial tachyarrhythmias\n   * Clinically significant resting bradycardia (\\\u003C 50 bpm)\n   * The mean QTcF \\>450msec following three consecutive ECG tests at baseline\n\n     : Screening test will be performed again for QTcF after the adjustment of electrolyte if QTcF \\>450msec and the electrolyte is not within the normal range.\n   * Medical history of clinically confirmed myocardial infarction\n   * Medical history of unstable angina (within last 12 months)\n   * Other clinically significant cardiac disease\n4. Patients with T315I point mutations\n5. Patients with central nervous system involvement as cytopathologically confirmed\n6. Severe or uncontrolled chronic disease\n7. Significant medical history of congenital or acquired bleeding disorders that are not related to leukemia\n8. Patients who previously received radiotherapy to at least 25% of the bodies with high portion of bone marrow\n9. Patients who received the major surgery within 4 weeks before the initiation of the IP administration or who failed to recover from the surgery that was performed before then.\n10. Patients who participated in other clinical study and are receiving any other IP.\n11. Patients who cannot give consent to the clinical study.\n12. Patients who have concurrently clinically significant primary malignancy\n13. Patients currently receiving treatment with a strong CYP3A4 inhibitors or strong CYP3A4 inducers or therapeutic Cumarin derivatives and that can neither stop the administration of these drugs before the start of the IP administration nor switch to other drugs.\n14. Patients who are currently receiving treatment with a medication that has the potential to prolong QT intervals and can neither stop the administration of the drugs before the start of the IP administration nor switch to other drugs. If subjects need to start such drug treatments during the study, they should contact the sponsor, IL-YANG PHARM. Co., Ltd.\n15. Gastrointestinal disorder or gastrointestinal disease that may result in a significant change in the absorption of the investigational product\n16. Medical history of acute or chronic pancreatitis within the past one year\n17. Acute or chronic liver, pancreas, or severe kidney disease that are not associated with the disease\n18. Patients known seropositive to human immunodeficiency virus (HIV), current acute or chronic hepatitis B (hepatitis B surface-antigen positive), hepatitis C, or cirrhosis. Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B (HBV DNA \\\u003C 500 IU\u002FmL or site specific local lab normal range lower limit assessed by investigator), and cured hepatitis C patients can be enrolled.\n19. Women patients that meet the following conditions should be excluded from the clinical study.\n\n    * Pregnancy\n    * Breastfeeding\n    * Pregnancy confirmed at screening pregnancy test\n    * Women of childbearing potential who is unwilling to use an appropriate method of contraception during the study\n20. Men patients who are unwilling to use and appropriate method of contraception during the study\n21. Patients who have hypersensitivity to active ingredient or any of the excipients of this investigational product","18 Years",{"count":94,"type":22},173,[51],"In a multinational, multicenter, single-arm, open-label and Phase III Radotinib clinical study, chronic phase Ph+ chronic myeloid leukemia patients with failure or intolerance to previous TKIs therapy including Imatinib will be recruited. In this phase 3 study, 173 subjects are expected to be enrolled in a single arm with the administration of Radotinib 400mg twice daily, which includes 10% of dropout rate.",[98,99,100,101],"Chronic Myeloid Leukemia, Chronic Phase","CML, Chronic Phase","CML, Refractory","CML - Philadelphia Chromosome",{"date":77,"type":33},{"date":104,"type":33},"2018-06-25",{"date":106,"type":22},"2027-12-31",{"name":38,"class":39},18,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":131,"locationsCount":132},"100415594","phase-2-safety-tolerability-pharmacokinetics-and-efficacy-study-of-radotinib-in-parkinsons-disease-100415594","NCT04691661","Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease","A Randomized Double-blind Placebo-controlled Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Radotinib in Parkinson's Disease","Inclusion Criteria:\n\n1. Male and Female from 40 to 80 years old;\n2. Diagnosed with \"Clinically Probable Parkinson's Disease\" according to the MDS clinical diagnostic criteria, with documented onset of symptoms per treating physician's records within three years of the screening visit;\n3. Positive DAT-scan (e.g. a striatal dopamine transporter deficit on dopamine transporter imaging by DaT-SPECT, characterized by crescent-shaped areas of asymmetrical aspect, or of symmetrical aspect but of uneven intensity, between the right and the left brain hemisphere) confirmed by local reading;\n4. Hoehn \\& Yahr stage ≤ 2.5;\n5. Without previous symptomatic treatment for PD disease and with current clinical state not requiring started dopaminergic therapy within 6 months from Baseline;\n6. Absence of a parkinsonian syndrome and other neurovascular comorbidities, confirmed by MRI\n7. Female subjects must be not of childbearing potential, e.g., documented evidence that they are surgically sterile (e.g., hysterectomy, partial hysterectomy, bilateral oophorectomy, bilateral tubal ligation), or postmenopausal (at least 12 months since last menses) or using highly effective method of birth control defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly, such as combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intra uterine devices (IUDs), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, condom, until at least one month after the last drug intake associated to a negative pregnancy test at screening;\n8. Covered by Health Insurance System;\n9. Able to understand and to sign the informed consent prior to screening;\n10. Blood Pressure (BP) and Heart Rate (HR) considered NCS by Investigator;\n11. Electrocardiogram (ECG) recording on a 12-lead ECG considered NCS by Investigator;\n12. Laboratory parameters within the normal range of the laboratory. Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator.\n\nExclusion Criteria:\n\n1. Atypical Parkinsonism or drug-induced Parkinsonism;\n2. Current, or within 60 days of screening, use of any prescription, investigational, or over the counter medication for the symptomatic treatment of PD or to slow the progression of PD.\n3. Prior use of dopaminergic therapy (e.g., levodopa, dopamine agonist, amantadine, rasagiline) for 30 or more days any time in the past;\n4. Cognitive impairment (MMSE ≤ 24);\n5. Active psychiatric disorder (mood disorders, hallucinations or delirium with strong functional impact and not controlled by medication or which happened during the last 3 months before inclusion);\n6. Severe or uncontrolled chronic disease;\n7. Significant medical history of congenital or acquired bleeding disorders;\n8. Treatment by Deep Brain Stimulation or continuous infusion of apomorphin\u002Fdopa gel;\n9. Any below impaired cardiac function:\n\n   * LVEF \\\u003C45% or \\\u003C lower bound of normal limit of study site (whichever higher), confirmed by echocardiogram (if the subject has already carried out this examination during the last month before inclusion, he\u002Fshe will be exempted from retaking this examination, but he\u002Fshe will have to present the echocardiogram as well as the cardiologist's report. If not, this exam should be performed during the screening period)\n   * Subjects who cannot have QT intervals measured according to ECG\n   * Complete left bundle branch block\n   * Subjects with cardiac pacemakers\n   * Subjects with congenital long QT syndrome or the family history of known long QT syndrome\n   * History of, or presence of symptomatic ventricular or atrial tachyarrhythmias\n   * Clinically significant resting bradycardia (\\\u003C 50 bpm).\n   * Mean QTcF \\>450msec following three consecutive ECG tests at baseline: Screening test will be performed again for QTcF after the adjustment of electrolyte if QTcF \\>450msec and the electrolyte is not within the normal range\n   * Medical history of clinically confirmed myocardial infarction\n   * Medical history of unstable angina (within last 12 months)\n   * Other clinically significant cardiac disease (e.g. congestive heart failure, or uncontrolled hypertension)\n10. Participation in other investigational drug trials within 30 days prior to Screening;\n11. Any concomitant medication or medication excluded that could put subject at risk, or interfere with study evaluations;\n12. Subjects currently receiving treatment with a strong CYP3A4 inhibitors (e.g. erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil) or strong CYP3A4 inducers (e.g. dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbitol, St. John's Wort) or therapeutic Cumarin derivatives (e.g. warfarin, acenocoumarol, phenprocoumon) and that can neither stop the administration of these drugs before the start of the IP administration nor switch to other drugs\n13. Subjects who are currently receiving treatment with a medication that has the potential to extend QT intervals and can neither stop the administration of the drugs before the start of the IP administration nor switch to other drugs (list of medications that have the potential to prolong QT interval is provided in the Appendix II) If subjects need to start such drug treatments during the study, this will be discussed with the sponsor, IL-YANG PHARM. Co., Ltd.\n14. Subjects who are currently receiving treatment with P-gp inducers (e.g. (Ritonavir, Saquinavir, Nelfinavir, Indinavir, Amprenavir, Tipranavir…), Apalutamide, Estrone, Estriol, Trazodone, Vincristine, Tamoxifen, Doxorubicin, Carbamazepine, Oxcarbazepine, Fosphenytoin, Lorlatinib, Phenobarbital, Phenytoin, Propofol, beclomethasone, Dexamethasone, Prednisone, Hydrocortisone, Diclofenac, Rifampicin, Reserpine, Nifedipine, Digoxine, Amiodarone, Spironolactone, Levothyroxine, Tacrolimus, Sirolimus, St. John's Wort (herbal ingredient)) and that can neither stop the administration of these drugs before the start of the IP administration nor switch to other drugs;\n15. Gastrointestinal disorder or gastrointestinal disease that may result in a significant change in the absorption of the investigational product;\n16. Medical history of acute or chronic pancreatitis within the past one year;\n17. Acute or chronic liver, pancreas, or severe kidney disease that are not associated with the disease;\n18. Subjects known seropositive to human immunodeficiency virus (HIV), current acute or chronic hepatitis B (hepatitis B surface-antigen positive), hepatitis C, or cirrhosis. Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B (HBV DNA \\\u003C 500 IU\u002FmL or site specific local lab normal range lower limit assessed by investigator), and cured hepatitis C subjects can be enrolled;\n19. Men subjects who are unwilling to use and appropriate method of contraception during the study;\n20. Subjects who have hypersensitivity to active ingredient or any of the excipients of this investigational product;\n21. Any medical condition that might interfere with the protocol except those defined in Section 5.3 of the study protocol;\n22. Subject unable to attend scheduled visits or to comply to the protocol;\n23. Subject under legal guardianship or judicial protection;\n24. Subject in the exclusion period of another protocol;\n25. No possibility of contact in case of emergency.","40 Years","80 Years",{"count":119,"type":22},40,[121],"PHASE2","This is a safety, tolerability, pharmacokinetic and efficacy study in subjects with Parkinson's disease",[124],"Parkinson Disease","2024-07-15",{"date":127,"type":33},"2024-07-16",{"date":129,"type":33},"2021-09-09",{"date":83,"type":22},{"name":38,"class":39},7,""]